Benzinga | Oct 1, 2020 08:15AM EDT

CNS Pharmaceuticals GMP Manufacturer Partner NCK A/S Receives Certificate of Analysis For Active Pharma Ingredient

HOUSTON, Oct. 1, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the Company's GMP manufacturer partner NCK A/S, received a Certificate of Analysis (CoA) for its Active Pharma Ingredient (API), clearing it for use in the production of Berubicin.